We determined the renal radiation dose of a series of 111In-labeled peptides using animal SPECT. Because the animals’ health deteriorated, renal toxicity was assessed. Methods: Wild-type and megalin-deficient mice were imaged repeatedly at 3- to 6-wk intervals to quantify renal retention after injection of 40–50 MBq of 111In-diethylenetriaminepentaacetic acid– labeled peptides (octreotide, exendin, octreotate, neurotensin, and minigastrin analogs), and the absorbed kidney radiation doses were estimated. Body weight, renal function parameters, and renal histology were determined at 16–20 wk after the first scan and compared with those in naive animals. Results: Be-cause of high renal retention, 111In-diethylenetriaminepentaace-tic acid–exend...
Purpose: Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used for tumou...
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs such as octreoti...
textabstractAim: In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin an...
We determined the renal radiation dose of a series of In-111-labeled peptides using animal SPECT. Be...
Contains fulltext : 89547.pdf (publisher's version ) (Closed access)We determined ...
Radiolabelled peptides used for peptide receptor radionuclide therapy are excreted mainly via the ki...
Neuroendocrine tumors overexpressing somatostatin receptors can be treated with peptide-receptor rad...
High kidney radiation doses during clinical peptide receptor radionuclide therapy (PRRT) with beta-p...
Contains fulltext : 51440.pdf (publisher's version ) (Closed access)Nephrotoxicity...
High kidney radiation doses during clinical peptide receptor radionuclide therapy (PRRT) with b-part...
Radiolabeled somatostatin analogs have been shown to be important radiopharmaceuticals for tumor dia...
Item does not contain fulltextAIM: In peptide receptor radionuclide therapy (PRRT) using radiolabell...
Radiolabeled somatostatin analogs have been shown to be important radiopharmaceuticals for tumor dia...
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs such as octreoti...
Purpose: Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used for tumou...
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs such as octreoti...
textabstractAim: In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin an...
We determined the renal radiation dose of a series of In-111-labeled peptides using animal SPECT. Be...
Contains fulltext : 89547.pdf (publisher's version ) (Closed access)We determined ...
Radiolabelled peptides used for peptide receptor radionuclide therapy are excreted mainly via the ki...
Neuroendocrine tumors overexpressing somatostatin receptors can be treated with peptide-receptor rad...
High kidney radiation doses during clinical peptide receptor radionuclide therapy (PRRT) with beta-p...
Contains fulltext : 51440.pdf (publisher's version ) (Closed access)Nephrotoxicity...
High kidney radiation doses during clinical peptide receptor radionuclide therapy (PRRT) with b-part...
Radiolabeled somatostatin analogs have been shown to be important radiopharmaceuticals for tumor dia...
Item does not contain fulltextAIM: In peptide receptor radionuclide therapy (PRRT) using radiolabell...
Radiolabeled somatostatin analogs have been shown to be important radiopharmaceuticals for tumor dia...
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs such as octreoti...
Purpose: Radiolabelled somatostatin analogues, such as octreotide and octreotate, are used for tumou...
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs such as octreoti...
textabstractAim: In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin an...